Side-by-side · Research reference
LivagenvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BPhase 3HUMAN-REVIEWED8/39 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
Livagen
Thymosin α-1
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
—
—
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
Thymosin α-1
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
—
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Human data
None in provided literature
—
Frequency
—
2× weekly (Mon/Thu typical)
Lower / starter dose
—
0.8 mg per injection
Duration
—
6–12 months for chronic indications
Reconstitution
—
Sterile water for injection per vial label
Timing
—
No specific time
Half-life
—
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
Livagen
Thymosin α-1
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
—
Injection site reaction
—
Erythema, mild discomfort
GI symptoms
—
Rare nausea
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Pregnancy / OB
—
Avoid
Absolute Contraindications
Livagen
—Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
Livagen
—Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
Livagen
Thymosin α-1
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
2× weekly, e.g. Monday + Thursday.
4. Storage
—
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
—
27–31G, 4–8 mm insulin syringe.